Synapticure
@synapticure.bsky.social
Cutting-edge telemedicine for patients with Alzheimer's and related Dementia, Parkinson’s, ALS and more. 🌐 synapticure.com | 📞(855) 255-5917
BCI has the chance to restore the little things we take for granted as healthy adults every day -- communication, moving a mouse, and hopefully someday replacing lost control of movement. We're grateful for the chance to build awareness for these and other programs in ALS.
October 23, 2025 at 4:41 PM
BCI has the chance to restore the little things we take for granted as healthy adults every day -- communication, moving a mouse, and hopefully someday replacing lost control of movement. We're grateful for the chance to build awareness for these and other programs in ALS.
Click the link above to register and connect with patients who are using Neuralink today to hear about their journey to BCI, their decision to join the trial, and how it has changed their lives. Please feel free to submit questions in advance in the registration link.
October 23, 2025 at 4:41 PM
Click the link above to register and connect with patients who are using Neuralink today to hear about their journey to BCI, their decision to join the trial, and how it has changed their lives. Please feel free to submit questions in advance in the registration link.
If you're building something in #neurodegeneration, let's build it together, with patient-derived platforms that bring you closer to clinical relevance.
Let’s make a difference together ➡️ https://www.synapticure.com/for-partners/research
#partnering #biotech #drugdiscovery
Let’s make a difference together ➡️ https://www.synapticure.com/for-partners/research
#partnering #biotech #drugdiscovery
July 25, 2025 at 10:00 AM
If you're building something in #neurodegeneration, let's build it together, with patient-derived platforms that bring you closer to clinical relevance.
Let’s make a difference together ➡️ https://www.synapticure.com/for-partners/research
#partnering #biotech #drugdiscovery
Let’s make a difference together ➡️ https://www.synapticure.com/for-partners/research
#partnering #biotech #drugdiscovery
Learn more about our study here https://www.cell.com/stem-cell-reports/fulltext/S2213-6711%2823%2900015-2 or visit
🔍 To learn more about our research visit https://www.synapticure.com/for-partners/research
#precisionmedicine #neurodegeneration #biomarkers
🔍 To learn more about our research visit https://www.synapticure.com/for-partners/research
#precisionmedicine #neurodegeneration #biomarkers
Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
In this article, de Majo et al. present a novel 3D iPSC-derived model to study neurodegenerativedisorders such as ALS and FTD. When devoid of GRN expression, these cultures presentfeatures of ALS- and FTD-associated pathology hardly ever observed in vitro. Thesephenotypes are shown to be primarily driven by diseased astrocytes and can be rescuedby pro-granulin supplementation.
www.cell.com
July 16, 2025 at 7:40 PM
Learn more about our study here https://www.cell.com/stem-cell-reports/fulltext/S2213-6711%2823%2900015-2 or visit
🔍 To learn more about our research visit https://www.synapticure.com/for-partners/research
#precisionmedicine #neurodegeneration #biomarkers
🔍 To learn more about our research visit https://www.synapticure.com/for-partners/research
#precisionmedicine #neurodegeneration #biomarkers
This allows us to ask meaningful questions about how cellular phenotypes map back to clinical trajectories.
💡It’s one way we’re trying to make preclinical data more clinically relevant from the start.
💡It’s one way we’re trying to make preclinical data more clinically relevant from the start.
Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
In this article, de Majo et al. present a novel 3D iPSC-derived model to study neurodegenerativedisorders such as ALS and FTD. When devoid of GRN expression, these cultures presentfeatures of ALS- and FTD-associated pathology hardly ever observed in vitro. Thesephenotypes are shown to be primarily driven by diseased astrocytes and can be rescuedby pro-granulin supplementation.
www.cell.com
July 16, 2025 at 7:40 PM
This allows us to ask meaningful questions about how cellular phenotypes map back to clinical trajectories.
💡It’s one way we’re trying to make preclinical data more clinically relevant from the start.
💡It’s one way we’re trying to make preclinical data more clinically relevant from the start.